Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selepressin in Septic Shock (SEPSIS-ACT)
NCT02508649Phase 3Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Oct 2017
- Modality
- Peptides
- Countries
- 5
01
Overview
A Phase 3 trial of selepressin in septic shock, sponsored by Ferring Pharmaceuticals. Started Jul 2015; status: terminated.
02
Drugs
selepressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02508649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508649.